Expression and prognostic significance of epithelial cell transforming sequence 2 in invasive breast cancer
10.3760/cma.j.cn115455-20220428-00377
- VernacularTitle:上皮细胞转化序列2在浸润性乳腺癌中的表达及其预后意义
- Author:
Zhiping LIN
1
;
Jinfa LIU
;
Xiaoyu XIAO
;
Jiarong MENG
Author Information
1. 联勤保障部队第九〇九医院厦门大学附属东南医院病理科，漳州 363000
- Keywords:
Breast neoplasms;
Epithelial cell transforming sequence 2;
Survival analysis;
Prognosis
- From:
Chinese Journal of Postgraduates of Medicine
2023;46(9):780-785
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the expression and prognostic significance of epithelial cell transforming sequence 2 (ECT2) in invasive breast cancer.Methods:The clinical data of 165 cases of invasive breast cancer treated in the 909th Hospital of Joint Logistics Support Force from January 2018 to June 2021 were retrospectively analyzed, the tumor tissues and corresponding normal tissues adjacent to the cancer were collected. The tumor tissues of breast cancer and adjacent normal tissues were stained with ECT2 immunohistochemistry. The relationship between the expression of ECT2 protein in different tissues and pathological and clinical data was analyzed. Multivariate Logistic regression was used to analyze the factors affecting the high expression of ECT2 protein. Kaplan-Meier method was used to compare the total survival time of breast cancer patients with high expression of ECT2 and low expression of ECT2 by Kmplot online survival analysis of public databases.Results:The expression of ECT2 in breast cancer tissues was significantly higher than that in adjacent normal tissues: 57.58% (95/165) vs. 12.73% (21/165) ( χ2 = 76.19, P<0.01). The patients with high expression of ECT2 had worse histopathological grade: grade G 1 30.53% (29/95) vs. 57.14% (40/70), grade G 2 40.00% (38/95) vs. 28.57% (20/70), grade G 3 29.47% (28/95) vs. 14.20% (10/40), higher lymph node metastasis: 71.58% (68/95) vs. 7.14% (5/70), worse TNM stage: stage Ⅰ 15.79% (15/95) vs. 34.29% (24/70), stage Ⅱ 27.37% (26/95) vs. 27.14% (19/70), stage Ⅲ 41.05% (39/95) vs. 28.57% (20/70), stage Ⅳ 15.79% (15/95) vs. 10.00% (7/70), higher proportion of menopause: 60.00% (57/95) vs. 44.29% (31/70) and higher Ki-67 proliferation index: 74.74% (71/95) vs. 58.57% (41/70) ( P<0.05). Lymph node metastasis ( OR = 2.764, P = 0.038), histopathological grade G 3( OR = 1.942, P = 0.010), TNM stage Ⅳ ( OR = 2.586, P<0.001), Ki-67 proliferation index greater than 14% ( OR = 1.376, P = 0.006) were the influencing factors of high expression of ECT2 protein in breast cancer patients. The overall survival of ECT2 patients with high expression of breast cancer was even worse ( P<0.05). Conclusions:The expression of ECT2 protein is increased in invasive breast cancer. The prognosis of breast cancer patients with high expression of ECT2 is even worse. ECT2 may be a potential molecular target for breast cancer treatment.
